The Advanced Wound Management Division of Smith & Nephew, St. Petersburg, Florida, has introduced a foam dressing kit for negative pressure wound therapy (NPWT). The new dressing kits will be launched in the first quarter of 2009, giving wound care professionals the freedom to select either a gauze or foam wound interface from a single NPWT device manufacturer. The new foam kits will be supplied sterile and are available in 4 sizes. It is a single-use product designed to be clinically effective and easy to use.
The new kits are intended to be used in conjunction with Smith & Nephew NPWT systems to deliver negative pressure to wounds. Smith & Nephew NPWT systems are intended for patients who would benefit from a suction device and are appropriate on the following types of wounds: pressure ulcers, diabetic/neuropathic ulcers, venous insufficiency ulcers, traumatic wounds, postoperative and dehisced surgical wounds, explored fistulas, and skin flaps and grafts.
The company has also launched a new product to expand the Acticoat family. Acticoat Flex is designed to support clinicians dealing with injuries at high risk of infection, using the manufacturer's Silcyrst nanocrystalline silver technology. It is also conformable to awkward anatomical areas, such as the face and hands, to improve comfort during wear. Initially, the product will be available in Canada, launching in the United States and Europe in 2009.
[black up pointing small triangle] Information:http://www.smith-nephew.com
Derma Sciences, Princeton, New Jersey, announced the first study patient has been entered into the company's Phase 2 study of its drug candidate, DSC127. Enrollment of the 75-patient study, looking into the drug's ability to accelerate healing in diabetic foot ulcers, is expected to be completed within 12 months. Extensive preclinical studies have shown that DSC127-a biologically active angiotensin analog-significantly increases wound healing rates, notably in reliable and validated diabetic animal models, according to the company. DSC127, a topically applied pharmaceutical, has been shown to promote healing in a variety of ways: by increasing keratinocyte proliferation, extracellular matrix production, and vascularization.
[black up pointing small triangle] Information:http://www.dermasciences.com
ConvaTec, Skillman, New Jersey, a world-leading developer and marketer of innovative medical technologies for community and hospital care, has received the Frost & Sullivan 2008 North American Growth Strategy Leadership Award for the advanced wound management market. This award, presented to the company that has demonstrated an exceptional long-term growth strategy within its own industry, was bestowed at the annual 2008 Excellence in Healthcare Awards Banquet in San Antonio, Texas. In making the award, Frost & Sullivan commended ConvaTec for its product innovations and strong brands, as well as support and collaboration with wound care specialists.
[black up pointing small triangle] Information:http://www.convatec.com
Wound Care Innovations, LLS, Fort Worth, Texas, a subsidiary of Wound Management Technologies, Inc, has received 501(k) clearance from the US Food and Drug Administration for a new wound management product using their patented hydrolyzed collagen technology. The product combines hydrolyzed collagen with the healing properties of polysulfated glycosaminoglycan (PSGAG) and will initially be available in gel form. It has been cleared and indicated for topical use in the management of chronic and acute wounds and dermal ulcers, including the management of: Stages I to IV pressure ulcers, venous ulcers, diabetic ulcers, superficial and partial-thickness burns, surgical wounds, traumatic wounds, superficial wounds, ulcers resulting from arterial insufficiency, and grafted wounds and donor sites.
[black up pointing small triangle] Information:http://www.celleraterx.com
Ivivi Technologies, Inc, Montvale, New Jersey, has received US Food and Drug Administration 510(k) clearance for the company's currently marketed targeted pulsed electromagnetic field (tPEMF) therapeutic products. The 510(k) Substantial Equivalence Determination specifically covers the company's SofPulse Models 912-M10, Roma(3), and Torino II products, which are indicated for the palliative treatment of postoperative pain and edema in superficial soft tissue. Targeted pulsed electromagnetic field therapy delivers signals that reduce pain and edema associated with inflammation. These signals have demonstrated reductions in patient morbidity by accelerating reduction of acute postoperative pain and edema and have demonstrated lower pharmacological analgesic use in a recently published randomized controlled trial.
[black up pointing small triangle] Information:http://www.ivivitechnologies.com